Association between Immunohistochemical profile and Clinicopathological appearance in Breast Cancer : A 7 year review from Mahdieh Radiotherapy Center, Hamadan, Iran

Kamal Mohammadian; Abdolazim  Sedighi Pashaki; Ehsan Akbari Hamed; Sepideh  Behnood; Mohammad  Abbasi; Mohammad  Babaei; Afsaneh  Madah Safaee; Tayebeh  Torkaman

Reports of Radiotherapy and Oncology

The Official Journal of ISCO

Current Issue All Issues In Press Accepted Manuscripts Search

Reviewer and AE Registration Form Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support

Authors Guide Submit Manuscript

Association between Immunohistochemical profile and Clinicopathological appearance in Breast Cancer : A 7 year review from Mahdieh Radiotherapy Center, Hamadan, Iran

Author(s):

Kamal Mohammadian¹,

Abdolazim Sedighi Pashaki¹,

Ehsan Akbari Hamed^1,*,

Sepideh Behnood¹,

Mohammad Abbasi²,

Mohammad Babaei³,

Afsaneh Madah Safaee³,

Tayebeh Torkaman¹

1Department of Radiation Oncology, Mahdieh Hospital, Hamadan, Iran

2Department of Hematology Oncology, Imam Khomeini Hospital, Hamadan University of Medical Sciences, Hamedan, Iran

3Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran

Reports of Radiotherapy and Oncology:Vol. 1, issue 3; 103-7

Published online:Dec 01, 2013

Article type:Research Article

Received:Sep 06, 2013

Accepted:Nov 01, 2013

How to Cite:Kamal MohammadianAbdolazim Sedighi PashakiEhsan Akbari HamedSepideh BehnoodMohammad AbbasiMohammad BabaeiAfsaneh Madah SafaeeTayebeh Torkamanet al.Association between Immunohistochemical profile and Clinicopathological appearance in Breast Cancer : A 7 year review from Mahdieh Radiotherapy Center, Hamadan, Iran.Rep Radiother Oncol.1(3):e2370.

Abstract

Introduction: Invasive breast cancer is the most common carcinoma in women. Immunohistochemistry classification now plays a key role in prognostic identification and prediction of outcome in this disease. Based on recent gene expression studies, immunohistochemical subtypes are as follows: Luminal A (ER+ and /or PR+, HER2-), luminal B (ER+ and /or PR+, HER2+), HER2+/ ER-, PR-, and basal-like (ER-, PR-, HER2-). These molecular differences have been shown to correlate with clinical features, such as survival, and sensitivity to treatment. In this study we evaluated the association between different subtypes with histological type, grade, tumor stage, lymph node positive ratio, lymph node status, recurrence, and survival.

Patients and Methods:We retrieved the clinical records of 580 patients with breast cancer who were treated at Mahdieh Institute of oncology in Hamadan, Iran between Oct 2004 and Oct 2011, and we evaluated clinicopathological data of these patients.

Result: mean age of patients was 47.22 ± 11.1 years. Of 573 patients, 116 (20.2%) were ER /PR+, HER2+, 257 (44.9%) were ER /PR+, HER2- , 72 (12.6%) were ER /PR- , HER2+ , 124 (21.6%) were ER /PR- , HER2- and 4 were not undefined. The estimated median follow up period for all subjects was 4.9 years (range 3 months to 6.9 years). The overall survival for all patients was 88.21% and the disease free survival was 83.7%. The interesting result of this study was the lower incidence of positive axillary lymph nodes in triple negative subtypes. Five-year relative survival rates were higher for patients with ER/PR+ and negative lymph nodes (p< 0.05).

Conclusion: This study highlighted the importance of immunohistochemical subtypes. As our patients were good representatives of breast cancer in western Iran and this study showed some differences with literature, further research should be directed at standardization of molecular and immunohistochemical methods in our country.

Keywords

Fulltext

Full text is available in the PDF.

References

1.
References are available in the PDF.

comments